We spoke to Professor Morie Getz at ASH 2018 about the current unmet needs in treatment of hereditary TTR amyloidosis, antisense technology, inotersen and the NEURO-TTR study.
1. What is hereditary TTR amyloidosis and what are the unmet needs in its treatment? (0:10)
2. Could you tell us a little about antisense technology and the mechanism of action of inotersen? (1:13)
3. What have been the major efficacy and safety findings of the NEURO-TTR study to date? (2:10)
4. What were the conclusions of the recent long-term update from the open-label extension of NEURO-TTR? (2:58)
5. What are the next steps in the clinical development of inotersen? (3:41)
Speaker’s disclosures: Morie A Gertz has received honoraria from Akcea and Ionis.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, December 1–4, 2018.
Share this Video
Related Videos In Haematology
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!